Navigation Links
EUSA Pharma Divests Monoclonal Antibody Research Business and Early-Stage Oncology Product
Date:5/1/2008

Strategic Transactions Increase EUSA's Focus on Late-Stage and Marketed

Products

DOYLESTOWN, Pennsylvania and OXFORD, England, May 1 /PRNewswire/ -- EUSA Pharma Inc ('EUSA'), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced that it has divested its monoclonal antibody research business to the French company International Drug Development (IDD). Concurrently, EUSA has divested its recombinant L-asparaginase therapeutic research program for acute lymphoblastic leukemia to the Alize Pharma Group. EUSA acquired both the antibody business and oncology program as part of its 2007 acquisition of OPi SA.

"These two transactions further underline EUSA's ongoing success in divesting early-stage programs while retaining a clear strategic focus on late-stage and marketed products," said Bryan Morton, Chief Executive of EUSA Pharma. "As we continue to rapidly build our business around our commercial infrastructure in the US and Europe, we are creating the opportunity to compete effectively with major players as an attractive partner for companies seeking specialist transatlantic commercialization and late-stage development expertise in the oncology, pain control and critical care areas."

EUSA's antibody research business is based in Dardilly, France, and consists of a team of research and development scientists, laboratories and a library of approximately 600 murine antibodies, of which a high proportion are currently characterized. The fully human anti-interleukin-6 antibody, which EUSA recently out-licensed to GlaxoSmithKline, was the first therapeutic antibody to arise from this library. Other antibodies derived from the library target indications in oncology and inflammation.

The divestment agreement for EUSA's recombinant L-asparaginase therapeutic research program includes an option for the company to license back any resulting product.
'/>"/>

SOURCE EUSA Pharma Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... The report provides qualitative insights on key market ... the market, in order to provide information about the ... market sizes for each sub-segment of the market and ... also includes analysis of the company profiles of the ... performances, product portfolios, and developments of each company. The ...
(Date:11/27/2014)... First articles published now ... Elsevier , a world-leading provider of scientific, technical ... announce the launch of a new journal: ... The launch of Extreme Mechanics Letters is ... of applied sciences such as micro and nanotechnologies, biotechnologies, ...
(Date:11/26/2014)... 26, 2014 The report on the ... segments the concerned market for revenue forecasts and market ... CAGR of 51.9% from 2013 to 2018. At the ... value of $1,415.6 million by 2018. , Browse through ... TOC for information about the market segmentation and in-depth ...
(Date:11/26/2014)... -- The announced sales of three healthcare units within ... expand in non-healthcare areas, says Kalorama Information. Siemens hasn,t ... says that  Siemens is the third largest company in ... IVD market , with 5.5 billion in IVD revenues ... likely affect IVD market shares.  Siemens ...
Breaking Biology Technology:Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 2Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 3Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 4Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 5Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 2Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 3Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 2Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 3Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor 4Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2
... Product Suite and Addresses Sample Preparation Bottlenecks -HOPKINTON, ... (Nasdaq: CALP ), a leading provider ... life sciences research, today launched the Zephyr Genomics ... for molecular biology applications. The inclusion of pre-installed ...
... Double Helix Consulting US (DHC US), headed by ... of highly experienced strategic pricing, reimbursement and market ... industry as well as strong commercial, governmental and ... to clients in the pharmaceutical, biotechnology and medical ...
... 26 /PRNewswire-Asia/ -- Sinovac Biotech Ltd.,(NYSE Alternext ... in China, today,announced its wholly owned subsidiary, ... approval from China,s Ministry of Agriculture to,conduct ... animal rabies,vaccine with independent intellectual property rights. ...
Cached Biology Technology:Caliper Life Sciences Introduces Zephyr Genomics Workstation for Automated Liquid Handling 2Caliper Life Sciences Introduces Zephyr Genomics Workstation for Automated Liquid Handling 3London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions 2Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine 2Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine 3Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine 4
(Date:11/21/2014)... 19, 2014  Earlier this year Donald Spector ... and one of the most prolific inventors in the ... transmitted from Smartphones to third party agencies. Spector envisioned ... one of the earliest known patents in this area. ... the military, child care, elder care and hospital applications. ...
(Date:11/21/2014)...   Atmel® Corporation (NASDAQ: ATML ... technology solutions, today launched the industry,s first family of ... V cc range from 1.7V to 5.5V. The ... 2 C bus communication speeds, and are available with ... ideal for consumer, industrial, computer, and medical applications. ...
(Date:11/18/2014)... , Nov. 17, 2014 The Parenteral Drug Association ... regulatory agencies will speak and at least seven more will ... at the Omni Shoreham Hotel in Washington D.C. ... again to have significant support from the regulatory agencies in ... Europe in our effort to help advance the ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... at the Universities of Bristol, Florence, and Western Australia, might ... with the disorder. The faces we see in the ... points in a face-space, said Elizabeth Pellicano of the University ... average, or most typical, face, with more distinctive faces lying ...
... by investigators at St. Jude Childrens Research Hospital provide ... or Gleevec, which has revolutionized the treatment of chronic ... of a particularly aggressive form of acute lymphoblastic leukemia ... activity of a specific molecule, a strategy aimed at ...
... It appears that chemical warfare has been around a ... about 100 million years, give or take a little. ... has identified a soldier beetle, preserved almost perfectly in amber, ... fight off an attacker when an oozing flow of sap ...
Cached Biology News:Children with autism don't adapt as readily to unfamiliar faces 2St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia 2Amber specimen captures ancient chemical battle 2Amber specimen captures ancient chemical battle 3
... Since the Flp-In System creates isogenic ... equivalent levels of the protein of ... in Figure 3. In this experiment ... (CAT) was subcloned into pcDNA5/FRT and ...
For the quantitative determination of cyclic AMP (cAMP) concentrations in cell culture supernates, serum, plasma, saliva, urine and cell lysates....
SHEEP ANTI BOVINE LACTOPEROXIDASE...
Fast, sensitive quantitation of total MEK 1/2 concentration....
Biology Products: